Literature DB >> 29094450

Management of pediatric psoriasis with acitretin: A review.

Smriti Subedi1, Qian Yu1, Zeyu Chen1, Yuling Shi1.   

Abstract

Psoriasis is a chronic inflammatory disease of the skin which can occur at any age-group. Psoriasis in childhood is not uncommon and has genetic susceptibility but usually, an environmental trigger such as infection is thought to initiate the disease process. Pediatric psoriasis has profound effects on both physical and psychosocial health of the patient. Treatment of mild psoriasis can be done with topical therapies but those which do not respond to topical therapies can be treated with phototherapy and systemic therapies. The use of systemic therapies in childhood is mainly based on the published data, case series, expert opinion and the experience as there is the lack of controlled trials in the age group. Based on the experience retinoids are probably the second line drugs for the treatment of pediatric psoriasis which do not respond to topical therapies and phototherapy. Using acitretin in a low dose and with proper physical examinations and laboratory investigations will reduce the hazard of potential serious adverse events. This article gives the review of the use of acitretin in pediatric psoriasis.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  acitretin; pediatric; psoriasis; retinoid

Mesh:

Substances:

Year:  2017        PMID: 29094450     DOI: 10.1111/dth.12571

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

Review 1.  Efficacy and Safety of Tripterygium Wilfordii Hook F on Psoriasis Vulgaris: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Meng Lv; Jingwen Deng; Nan Tang; Yuejin Zeng; Chuanjian Lu
Journal:  Evid Based Complement Alternat Med       Date:  2018-04-22       Impact factor: 2.629

Review 2.  Pros and cons of using systemic acitretin in the paediatric population.

Authors:  Magdalena Sadowska; Joanna Narbutt; Małgorzata Skibińska; Aleksandra Lesiak
Journal:  Postepy Dermatol Alergol       Date:  2020-09-01       Impact factor: 1.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.